Cancer guide
By Cura Editorial Team ·
Usually silent in its early stages — most cases are found by PSA testing, and many are slow enough that active surveillance is the right first step.
Early signs, which ones need a same-week doctor visit, and what screening looks like.
Read the symptoms guideThe questions that shape treatment — biomarkers, staging, surgery, chemo, second opinions.
Read the questions guideRecent approvals and trial results — and the questions to ask your oncologist about whether any of it applies to you. Not every option fits every person.
Based on the phase 3 PSMAddition trial, the FDA approved Pluvicto with hormone therapy for PSMA-positive prostate cancer that still responds to hormone therapy.
May apply to: PSMA-positive, hormone-sensitive metastatic prostate cancer
Ask your oncologist:
Source: FDA
The FDA approved capivasertib (Truqap) with abiraterone after the phase 3 CAPItello-281 trial showed longer progression-free survival in tumors missing PTEN.
May apply to: PTEN-deficient, hormone-sensitive metastatic prostate cancer
Ask your oncologist:
Source: FDA
Reviewed September 25, 2026.
Email me when something new is approved for prostate cancer
Only real treatment news for this cancer, in plain language. Optional — the guide and Ask Cura stay free and anonymous. Unsubscribe anytime.
The signs that most often lead to a prostate cancer diagnosis are: new urinary symptoms — hesitancy, weak stream, waking to urinate; blood in urine or semen; bone pain, especially in the back or hips. Any of these lasting more than a couple of weeks is worth a same-week appointment, even though most turn out to be something else.
See a doctor promptly if a symptom is new, persistent, or getting worse rather than better. Describe when it started, how often it happens, and what makes it better or worse — that detail is what decides whether you get imaging or testing at the first visit.
Usually silent in its early stages — most cases are found by PSA testing, and many are slow enough that active surveillance is the right first step. PSA testing decisions typically begin between ages 45–55. Gleason score and MRI shape whether to watch or treat. Active surveillance is a legitimate option for many low-risk cancers.
Ask what the exact diagnosis is and how it is staged, what the treatment options are and in what order they would happen, what the goal of treatment is, which side effects to expect, and whether a second opinion or clinical trial makes sense for your situation.
Paste a pathology report, upload a scan summary, or just type the question you'd ask your oncologist if you had more than 15 minutes. Cura will answer in plain language.
Ask CuraWant occasional plain-language health explainers?
A short note now and then. No spam, unsubscribe anytime.
If a start date is on the calendar, or you feel lost between diagnosis and the first infusion, build a first-visit brief on the page: what's known, what's missing, what to ask. Homework, not a treatment plan.
Cura Brief is educational. It is not medical advice, a diagnosis, or a treatment plan. Confirm everything with your oncology team. If this is an emergency, call emergency services. Email is not an emergency line.
Prefer email? hello@curawellplan.com
Waiting for results is its own kind of hard. Cura has a plain-language guide to what the wait actually means — and what to do while you wait.
How long do biopsy results take?